104 related articles for article (PubMed ID: 2847323)
21. The capsid antigen of Epstein-Barr virus in nasopharyngeal carcinomas: comparison of serum antibody titre, cellular antigen content and histopathology.
Falser N
Arch Otorhinolaryngol; 1984; 239(1):15-23. PubMed ID: 6318710
[TBL] [Abstract][Full Text] [Related]
22. Nasopharyngeal mucosal changes in EB virus VCA-IgA antibody positive persons.
Li EJ; Tan BF; Zeng Y; Wang PZ; Zhong JM; Deng H; Zhu CS; Wei JN; Pan WJ
Chin Med J (Engl); 1985 Jan; 98(1):25-30. PubMed ID: 2988864
[No Abstract] [Full Text] [Related]
23. [Epstein-Barr virus capsid antigen (EB-VAC)-IgA antibody titer in splenectomized patients with Hodgkin's disease. A follow-up study].
Gunzer U; Nürnberger R
Verh Dtsch Ges Inn Med; 1974; 80():1619-23. PubMed ID: 4375897
[No Abstract] [Full Text] [Related]
24. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
[TBL] [Abstract][Full Text] [Related]
25. [Immunoglobulin A serum antibodies against the capsid antigen of Epstein-Barr virus in the differential diagnosis and follow-up of nasopharyngeal cancer].
Pavelka R; Popow-Kraupp T; Radaszkiewicz T
Wien Klin Wochenschr; 1985 Jul; 97(14):588-95. PubMed ID: 2996246
[TBL] [Abstract][Full Text] [Related]
26. [The nasopharyngeal carcinoma and Epstein-Barr virus (EBV) specific IgA (author's transl)].
Desgranges C
Pathol Biol (Paris); 1981 Dec; 29(10):587-9. PubMed ID: 6280123
[No Abstract] [Full Text] [Related]
27. Epstein--Barr virus-associated antibodies in IgG and IgA of nasopharyngeal carcinoma patients.
Yang CS; Yang HM; Yeh YS; Lynn TC
Comp Immunol Microbiol Infect Dis; 1979; 2(2-3):167-75. PubMed ID: 228890
[No Abstract] [Full Text] [Related]
28. Nasopharyngeal carcinoma and Epstein-Barr virus. I. Factors related to the anti-VCA antibody.
Lynn T; Tu S; Hirayama T; Kawamura A
Jpn J Exp Med; 1973 Apr; 43(2):121-33. PubMed ID: 4352111
[No Abstract] [Full Text] [Related]
29. [Fluctuation in Epstein-Barr virus-related antibody titers by age: response differences between the IgG antibodies to VCA and anti-EBNA antibodies].
Kumagai E; Tanaka R; Kumagai T; Katsuki T; Sawada S
Rinsho Byori; 1984 Jun; 32(6):666-70. PubMed ID: 6092744
[No Abstract] [Full Text] [Related]
30. Epstein-Barr virus-associated antibodies and serum biochemistry in nasopharyngeal carcinoma.
Lynn TC; Hsieh RP; Chuang CY; Huang SC; Hsieh T; Tu SM
Laryngoscope; 1984 Nov; 94(11 Pt 1):1485-8. PubMed ID: 6092804
[TBL] [Abstract][Full Text] [Related]
31. Nasopharyngeal carcinoma and Epstein-Barr virus. II. Clinical course and the anti-VCA antibody.
Lynn T; Tu S; Hirayama T; Kawamura A
Jpn J Exp Med; 1973 Apr; 43(2):135-44. PubMed ID: 4352112
[No Abstract] [Full Text] [Related]
32. Epstein-Barr-specific IgA in nasopharyngeal cancer.
Lancet; 1978 Jun; 1(8078):1345-6. PubMed ID: 78104
[No Abstract] [Full Text] [Related]
33. Epstein-Barr virus-related antibody. Changes in titers after therapy for nasopharyngeal carcinoma.
Neel HB; Taylor WF
Arch Otolaryngol Head Neck Surg; 1990 Nov; 116(11):1287-90. PubMed ID: 2173618
[TBL] [Abstract][Full Text] [Related]
34. Nasopharyngeal carcinoma due to Epstein-Barr virus: serologic tests.
Smith TF
Mayo Clin Proc; 1985 Mar; 60(3):205-6. PubMed ID: 2983152
[No Abstract] [Full Text] [Related]
35. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus antibodies in patients with laryngeal and hypopharyngeal cancer.
Morshed K; Polz-Dacewicz M; Szymański M; Rajtar B; Ziaja-Sołtys M; Gołabek W
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):227-31. PubMed ID: 15323196
[TBL] [Abstract][Full Text] [Related]
37. Epstein Barr virus (EBV) antibodies in the diagnosis of NPC--comparison between IFA and two commercial ELISA kits.
Chan SH; Soo MY; Gan YY; Fones-Tan A; Sim PS; Kaur A; Chew CT
Singapore Med J; 1998 Jun; 39(6):263-5. PubMed ID: 9803815
[TBL] [Abstract][Full Text] [Related]
38. ELISA for the detection of serum and saliva IgA against the BMRFI gene product of Epstein-Barr virus.
Nadala EC; Tan TM; Wong HM; Ting RC
J Med Virol; 1996 Sep; 50(1):93-6. PubMed ID: 8890046
[TBL] [Abstract][Full Text] [Related]
39. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
[TBL] [Abstract][Full Text] [Related]
40. Serological follow-up of children with infectious mononucleosis caused by Epstein-Barr virus.
Timár L; Koller M; Budai J
Acta Paediatr Acad Sci Hung; 1981; 22(3):243-9. PubMed ID: 6272540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
